US · NTRA
Natera, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Austin, CA 78753
- Website
- natera.com
Price · as of 2024-12-31
$207.28
Market cap 29.01B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $98.85 | -52.31% |
| Intrinsic Value(DCF) | $1,815.91 | +776.07% |
| Graham-Dodd Method(GD) | $1.95 | -99.06% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $8.97 | $139.89 | $3,994.46 | $0.00 | $0.00 |
| 2016 | $8.00 | $20.19 | $103.89 | $0.00 | $0.00 |
| 2017 | $9.29 | $21.45 | $0.00 | $0.00 | $0.00 |
| 2018 | $15.57 | $28.46 | $0.00 | $0.00 | $0.00 |
| 2019 | $38.29 | $37.02 | $4.00 | $0.00 | $0.00 |
| 2020 | $104.04 | $56.50 | $73.79 | $0.00 | $0.00 |
| 2021 | $38.98 | $29.77 | $1,136.50 | $0.00 | $0.00 |
| 2022 | $54.13 | $34.37 | $1,873.62 | $0.00 | $0.00 |
| 2023 | $89.06 | $55.05 | $2,672.04 | $0.00 | $0.00 |
| 2024 | $140.66 | $98.85 | $6,221.91 | $1.95 | $0.00 |
AI valuation
Our deep-learning model estimates Natera, Inc.'s (NTRA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $98.85
- Current price
- $207.28
- AI upside
- -52.31%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1,815.91
+776.07% upside
Graham-Dodd
$1.95
-99.06% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NTRA | Natera, Inc. | $207.28 | 29.01B | -52% | +776% | -99% | — | -92.12 | 14.68 | 10.34 | -113.19 | — | 14.68 | 60.30% | -13.10% | -11.22% | -19.42% | -59.87% | -12.28% | 0.16 | -20.80 | 4.00 | 3.73 | 5.12 | -5952.00% | 5675.00% | -12420.00% | 0.39% | 0.39 | 18.65% | 0.00% | 0.00% | 3.18% | -75.40 | 242.08 | 9.88 | 21.78 |
| BNTX | BioNTech SE | $110.23 | 26.51B | +25% | -21% | -31% | -45% | -32.97 | 1.15 | 8.12 | -15.84 | — | 1.23 | 80.32% | -47.77% | -24.18% | -3.42% | -37.96% | -2.98% | 0.01 | -99.86 | 7.45 | 7.26 | 25.90 | -17232.00% | -2796.00% | -10524.00% | -1.09% | 0.08 | -7.20% | 0.00% | 0.00% | 0.00% | -4.42 | -23.77 | 2.11 | 6.28 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| DXCM | DexCom, Inc. | $73.43 | 28.64B | +15% | -6% | -76% | -33% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| ILMN | Illumina, Inc. | $134.46 | 20.56B | -15% | -56% | -72% | -69% | 23.92 | 7.47 | 4.68 | 14.59 | — | 14.52 | 66.49% | 19.92% | 19.58% | 33.36% | 18.25% | 13.13% | 0.94 | 8.65 | 2.08 | 1.57 | 0.78 | -17074.00% | -69.00% | 3131.00% | 4.58% | 0.68 | 25.10% | 0.00% | 0.00% | 5.42% | 24.57 | 22.83 | 4.89 | 4.42 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| MTD | Mettler-Toledo Internatio… | $1,366.69 | 27.92B | -28% | -53% | -87% | -63% | 31.42 | -1155.46 | 6.78 | 23.96 | 851.91 | -26.22 | 57.52% | 27.78% | 21.59% | -1154.87% | 44.16% | 25.00% | -99.14 | 16.32 | 1.14 | 0.71 | 1.84 | 369.00% | 398.00% | -183.00% | 3.11% | 0.80 | 40.43% | 0.00% | 0.00% | 2.93% | 26.45 | 34.86 | 7.35 | 10.00 |
| PHG | Koninklijke Philips N.V. | $32.00 | 30.68B | +25% | -54% | -95% | -76% | 28.63 | 2.34 | 1.44 | 11.71 | — | -29.02 | 45.18% | 7.98% | 5.02% | 7.80% | 6.50% | 3.20% | 0.74 | 4.28 | 1.32 | 0.84 | 2.00 | -22400.00% | -104.00% | -3406.00% | 3.49% | 0.15 | 5.36% | 1.28% | 36.60% | 1.28% | 21.71 | 34.62 | 1.73 | 2.09 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| TEVA | Teva Pharmaceutical Indus… | $33.86 | 38.83B | +22% | -53% | — | -55% | 27.36 | 4.91 | 2.25 | 16.76 | — | -3.27 | 51.79% | 12.50% | 8.17% | 21.35% | 10.30% | 3.54% | 2.20 | 2.35 | 1.04 | 0.54 | 4.40 | -18276.00% | 431.00% | 5327.00% | 2.96% | 0.12 | 5.48% | 0.00% | 0.00% | 2.46% | 24.40 | 45.84 | 3.05 | 0.85 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
About Natera, Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
- CEO
- Steven Leonard Chapman
- Employees
- 4.42K
- Beta
- 1.63
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1,815.91 ÷ $207.28) − 1 = +776.07% (DCF, example).